Q-omics provides the consensus-scored ALG1L11P profile across patient tissues and cancer cell-line models. ALG1L11P expression is associated with patient survival in 16 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, ALG1L11P is differentially expressed in 7, with the highest sampling consensus in BRCA. Additionally, ALG1L11P RNA expression shows 14,755 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight BLCA, BRCA, and TGCT as cancer lineages where ALG1L11P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ALG1L11P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ALG1L11P survival associations across molecular data types. ALG1L11P RNA expression shows survival associations in the most cancer types (16). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ALG1L11P RNA expression–survival associations across cancer types. High ALG1L11P expression shows unfavorable associations in LUAD, LGG, UCEC and LIHC, but favorable associations in BLCA and HNSC. The BLCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .004). Together, the overview and detailed table identify BLCA as the clearest survival context for ALG1L11P RNA expression.
This table summarizes ALG1L11P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for ALG1L11P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ALG1L11P shows lower tumor expression in BRCA, READ, HNSC and KIRC and higher tumor expression in PAAD and CHOL. The BRCA box plot shows higher ALG1L11P RNA expression in normal versus tumor tissue (log2 FC = −0.259, t-test p < 0.001).
This table shows molecular features associated with ALG1L11P in patient tissues and cancer cell lines. In patient samples, ALG1L11P shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set.
